Before the STEVECO trial, there were no randomized controlled trial data in the chronic disease space; in its wake, has come a more robust landscape to establish an evidence base: During the 2024 Charing Cross (CX) International Symposium (April 23–25, London, UK), Stephen Black (Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, UK), Efthymios Avgerinos (Athens Medical Center and University of Athens, Greece), and Erin Murphy (Atrium Health’s Sanger Heart and Vascular Institute, Charlotte, USA) sat down with Houman Jalaie (University Hospital RWTH, Aachen, Germany), to discuss the STEVECO trial and how it provides necessary data on venous stenting for patients affected by chronic venous insufficiency.
The STEVECO (Stent versus conservative treatment in patients with deep venous obstruction) trial is a prospective, randomized, multicenter, 12-month trial comparing venous stenting using Optimed’s sinus-Venous stent to conservative treatment. The trial measured disease-specific quality of life (QoL), Venous Clinical Severity Score (VCSS), and patency in 63 patients who had either post-thrombotic syndrome (PTS) or non-thrombotic iliac vein lesions (NIVLs). The results of the study showed that symptomatic patients with deep venous obstruction who received the sinus-Venous dedicated venous stent had significant improvement in QoL after 12 months. There was also a significant improvement in VCSS and the pain disability index.
This video is sponsored by Optimed.
